Page 4 - Metropolis Healthcare

Metropolis Healthcare plunges 23% in two days on disappointing Q3 results

In Q4FY22, the company expects better profitability on account of higher QoQ volumes from large government contract and benefits of investments in digitization and marketing.

Metropolis Healthcare net profit dips 30% to Rs 41 cr in December quarter

Metropolis Healthcare on Friday said its net profit declined 29.69 per cent to Rs 41.2 crore for the third quarter ended December 31, 2021. The diagnostics chain had reported a net profit of Rs 58.6 core in the same period of previous fiscal. Revenues, however, increased to Rs 293.1 crore in the period under review as against Rs 274.7 crore in the same period of 2020-21 fiscal, Metropolis Healthcare said in a statement. "We have been able to grow our non-COVID revenue despite a sharp drop in volumes from a government contract. We have made increased investments in digital and marketing, manpower & customer experience initiatives in order to strengthen our brand. This has impacted margins which we believe is a short-term phenomenon," Metropolis Healthcare Promoter and Managing Director Ameera Shah noted. The company has been able to successfully complete the acquisition of Hitech Diagnostics during the third quarter which will enable it to scale up business, improve the B2C revenue

Budget 2022: Balanced and disciplined, says Metropolis Healthcare MD Shah

It is assuring to see that the annual Budget has majorly focused on women, youth, and rural development

Metropolis Healthcare board approves acquisition of Hitech Diagnostic

Metropolis Healthcare said its board approved the acquisition of Hitech Diagnostic Centre and its arm Centralab Healthcare Services in a combination of cash and equity shares deal.

Non-Covid biz not back to pre-pandemic levels: Metropolis Healthcare MD

In a Q&A, Ameera Shah says, however, that the impact of the second wave on her industry segment wasn't as bad as the first

Metropolis Healthcare advances 14%, hits new high on healthy Q4 results

The company's Q4 reported Ebitda margins expanded by 820 bps YoY at 33.2 per cent on the back of increased scale of business, strong cost optimization and automation efforts

Bet on these diagnostic stocks for up to 19% return as Covid-19 cases flare

According to the Union Health Ministry data, India recorded 1,03,558 coronavirus infections on Sunday, pushing the nationwide Covid tally to 1.25 crore

Metropolis Healthcare to acquire Chennai-based diagnostic lab for Rs 511 cr

Metropolis will acquire 100 per cent equity of Dr Ganesan's Hitech Diagnostic Centre in a cash and stock deal

Stocks to watch: HDFC Bank, Metropolis Healthcare, Wipro, Airtel, DHFL

Metropolis Healthcare said it will acquire Dr Ganesan's Hitech Diagnostic Centre

Metropolis Healthcare to buy Hitech Diagnostic Centre in a cash, stock deal

Diagnostic chain Metropolis Healthcare said it will acquire Dr Ganesan's Hitech Diagnostic Centre Pvt Ltd in a cash and stock combination deal, to strengthen its leadership position in southern India

Street rewards all but one of 12 companies that pruned share pledges

Sequent Scientific and Everyday Industries saw percentage shareholding pledged by promoters go down by over 44 per cent each and their shares rally by 68 per cent and 75 per cent, respectively

Thyrocare, Dr Lal PathLabs: Healthcare stocks can rally more, charts show

A new all time high shows bullish sentiment is here to stay in these stocks.

Healthcare services stocks rally; Thyrocare up 35% in 2 days post Q2 update

Thyrocare Technologies, Metropolis Healthcare and Dr. Lal PathLabs, hitting their respective record highs, were up 9 per cent to 17 per cent on the BSE in intra-day trade.

'Rules are different for public labs as compared to private labs'

Ameera Shah, promoter and managing Director of Metropolis Healthcare, says private labs have been at the forefront of medical testing.

Market Ahead, May 29: All you need to know before the opening bell

Today, a total of 31 companies including Voltas, Jubilant Life Sciences, and Metropolis Healthcare, are scheduled to announce their March quarter results

Metropolis Healthcare share price falls 14% after block deals

According to media reports, private equity giant Carlyle was looking to sell stake in Metropolis Healthcare

Metropolis Healthcare jumps 17% on strong long-term growth prospects

The brokerage expects the healthcare company to benefit from its aggressive B2C expansion, where it has expanded its network touch points by ~6.6X over the past 3.5 years

Coronavirus pandemic: Stocks of diagnostic firms could prove safe bets

Though details of Covid19-testing reimbursement are crucial to ascertain the earnings impact, other growth levers remain intact

Thyrocare Tech, Dr Lal Path Labs surge as pvt labs to conduct Covid-19 test

That apart, national laboratories have also been allowed to carry out clinical testing of Covid-19, as the number of cases went past 400 in India.

Metropolis, Thyrocare say they will start tests for coronavirus from today

They would start collecting samples for testing from today. For starters, this would happen in Mumbai